230 related articles for article (PubMed ID: 9130895)
1. Assessment of the role of serum luteinizing hormone and estradiol response to follicle-stimulating hormone on in vitro fertilization treatment outcome.
Loumaye E; Engrand P; Howles CM; O'Dea L
Fertil Steril; 1997 May; 67(5):889-99. PubMed ID: 9130895
[TBL] [Abstract][Full Text] [Related]
2. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
[TBL] [Abstract][Full Text] [Related]
3. Minimal stimulation IVF using clomiphene citrate and oral contraceptive pill pretreatment for LH suppression.
Branigan EF; Estes MA
Fertil Steril; 2000 Mar; 73(3):587-90. PubMed ID: 10689017
[TBL] [Abstract][Full Text] [Related]
4. The utility of a midcycle follicle-stimulating hormone boost in addition to human chorionic gonadotropin for timing of follicle aspiration in unstimulated in vitro fertilization cycles.
Lindheim SR; Sauer MV; Francis MM; Macaso T; Lobo R; Paulson RJ
Gynecol Obstet Invest; 1997; 43(2):76-8. PubMed ID: 9067710
[TBL] [Abstract][Full Text] [Related]
5. Increased progesterone/estradiol ratio in the late follicular phase could be related to low ovarian reserve in in vitro fertilization-embryo transfer cycles with a long gonadotropin-releasing hormone agonist.
Younis JS; Matilsky M; Radin O; Ben-Ami M
Fertil Steril; 2001 Aug; 76(2):294-9. PubMed ID: 11476775
[TBL] [Abstract][Full Text] [Related]
6. Implications of using follicle-stimulating hormone preparations depleted of luteinizing hormone to achieve follicular growth in in vitro fertilization.
Agrawal R; Conway GS; Engmann L; Bekir JS; Jacobs HS
Gynecol Endocrinol; 1998 Feb; 12(1):9-15. PubMed ID: 9526704
[TBL] [Abstract][Full Text] [Related]
7. A randomized prospective assessor-blind evaluation of luteinizing hormone dosage and in vitro fertilization outcome.
Gordon UD; Harrison RF; Fawzy M; Hennelly B; Gordon AC
Fertil Steril; 2001 Feb; 75(2):324-31. PubMed ID: 11172834
[TBL] [Abstract][Full Text] [Related]
8. [Correlation between serum inhibin B level after treatment with gonadotropin releasing hormone agonist and outcome of in vitro fertilization-embryo transfer].
Lin WQ; Yang HY; Lin JJ; Chen X; Ye BL
Zhonghua Fu Chan Ke Za Zhi; 2009 Apr; 44(4):260-2. PubMed ID: 19570462
[TBL] [Abstract][Full Text] [Related]
9. The influence of estradiol/follicle and estradiol/oocyte ratios on the outcome of controlled ovarian stimulation for in vitro fertilization.
Orvieto R; Zohav E; Scharf S; Rabinson J; Meltcer S; Anteby EY; Homburg R
Gynecol Endocrinol; 2007 Feb; 23(2):72-5. PubMed ID: 17454155
[TBL] [Abstract][Full Text] [Related]
10. [Effect of bushen tiaojing recipe on the quality of the oocytes and reproductive hormones in the follicular fluid in IVF-ET patients].
Liang Y; Du HL; Chang XF; Zhao SN; Lei LM
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2014 Aug; 34(8):911-6. PubMed ID: 25223171
[TBL] [Abstract][Full Text] [Related]
11. [Smoothing Gan Reinforcing Shen Method Adjuvantly Treated Poor Response of Diminished Ovari- an Reserve Patients in in vitro Fertilization and Embryo Transfer: a Clinical Study].
Zhang Z; Zhang XH; He TY
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2015 Oct; 35(10):1170-4. PubMed ID: 26677665
[TBL] [Abstract][Full Text] [Related]
12. The effect of human menopausal gonadotrophin and highly purified, urine-derived follicle stimulating hormone on the outcome of in-vitro fertilization in down-regulated normogonadotrophic women.
Westergaard LG; Erb K; Laursen S; Rasmussen PE; Rex S
Hum Reprod; 1996 Jun; 11(6):1209-13. PubMed ID: 8671425
[TBL] [Abstract][Full Text] [Related]
13. A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol.
Hohmann FP; Macklon NS; Fauser BC
J Clin Endocrinol Metab; 2003 Jan; 88(1):166-73. PubMed ID: 12519847
[TBL] [Abstract][Full Text] [Related]
14. Follicular phase serum levels of luteinizing hormone do not influence delivery rates in in vitro fertilization cycles down-regulated with a gonadotropin-releasing hormone agonist and stimulated with recombinant follicle-stimulating hormone.
Cabrera RA; Stadtmauer L; Mayer JF; Gibbons WE; Oehninger S
Fertil Steril; 2005 Jan; 83(1):42-8. PubMed ID: 15652885
[TBL] [Abstract][Full Text] [Related]
15. [Acupuncture combined with medication improves endocrine hormone levels and ovarian reserve function in poor ovarian response patients undergoing in vitro fertilization-embryo transplantation].
Dong XL; Ran JK; Zhang HJ; Chen K; Li HX
Zhen Ci Yan Jiu; 2019 Aug; 44(8):599-604. PubMed ID: 31475495
[TBL] [Abstract][Full Text] [Related]
16. Dynamics of the development of multiple follicles during ovarian stimulation for in vitro fertilization using recombinant follicle-stimulating hormone (Puregon) and various doses of the gonadotropin-releasing hormone antagonist ganirelix (Orgalutran/Antagon).
de Jong D; Macklon NS; Eijkemans MJ; Mannaerts BM; Coelingh Bennink HJ; Fauser BC;
Fertil Steril; 2001 Apr; 75(4):688-93. PubMed ID: 11287020
[TBL] [Abstract][Full Text] [Related]
17. Clinical effects of ovulation induction with recombinant follicle-stimulating hormone supplemented with recombinant luteinizing hormone or low-dose recombinant human chorionic gonadotropin in the midfollicular phase in microdose cycles in poor responders.
Berkkanoglu M; Isikoglu M; Aydin D; Ozgur K
Fertil Steril; 2007 Sep; 88(3):665-9. PubMed ID: 17292895
[TBL] [Abstract][Full Text] [Related]
18. A prospective randomized comparison of routine buserelin acetate and a decreasing dosage of nafarelin acetate with a low-dose gonadotropin-releasing hormone agonist protocol for in vitro fertilization and intracytoplasmic sperm injection.
Takeuchi S; Minoura H; Shibahara T; Tsuiki Y; Noritaka F; Toyoda N
Fertil Steril; 2001 Sep; 76(3):532-7. PubMed ID: 11532477
[TBL] [Abstract][Full Text] [Related]
19. Basal serum progesterone and history of elevated progesterone on the day of hCG administration are significant predictors of late follicular progesterone elevation in GnRH antagonist IVF cycles.
Venetis CA; Kolibianakis EM; Bosdou JK; Lainas GT; Sfontouris IA; Tarlatzis BC; Lainas TG
Hum Reprod; 2016 Aug; 31(8):1859-65. PubMed ID: 27301360
[TBL] [Abstract][Full Text] [Related]
20. Role of periovulatory luteinizing hormone concentrations during assisted reproductive technology cycles stimulated exclusively with recombinant follicle-stimulating hormone.
Esposito MA; Barnhart KT; Coutifaris C; Patrizio P
Fertil Steril; 2001 Mar; 75(3):519-24. PubMed ID: 11239535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
